Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation (original) (raw)
Related papers
Current issues in atrial fibrillation
ISRN cardiology, 2012
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It places an enormous burden on the patients, caregivers, and the society at large. While the main themes in the care of an AF patient have not changed over the years and continue to focus on stroke prevention, control of the ventricular, rate and rhythm maintenance, there have been a number of new developments in each of these realms. This paper will discuss the "hot" topics in AF in 2012 including new and upcoming medical and invasive management strategies for this condition.
Atrial fibrillation: Challenges and opportunities
Canadian Journal of Cardiology, 2006
A trial fibrillation (AF) is the most common sustained arrhythmia treated by physicians today. Despite decades of investigation and experience with the treatment of AF, many challenges remain. Contemporary challenges include the following examples: an incomplete understanding of the pathophysiology of AF; an increasing prevalence of AF; a lack of efficacy of and the presence of adverse effects from antiarrhythmic drug therapy; and suboptimal use of antithrombotic therapy for the prevention of stroke and thromboembolism. On the other hand, each of these challenges is associated with a number of opportunities for improved understanding and management of this vexing problem. The present overview will explore each of the challenges in the management of AF listed above and some of the opportunities associated with them.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2018
There are major challenges ahead for clinicians treating patients with atrial fibrillation (AF). The population with AF is expected to expand considerably and yet, apart from anticoagulation, therapies used in AF have not been shown to consistently impact on mortality or reduce adverse cardiovascular events. New approaches to AF management, including the use of novel technologies and structured, integrated care, have the potential to enhance clinical phenotyping or result in better treatment selection and stratified therapy. Here, we report the outcomes of the 6th Consensus Conference of the Atrial Fibrillation Network (AFNET) and the European Heart Rhythm Association (EHRA), held at the European Society of Cardiology Heart House in Sophia Antipolis, France, 17-19 January 2017. Sixty-two global specialists in AF and 13 industry partners met to develop innovative solutions based on new approaches to screening and diagnosis, enhancing integration of AF care, developing clinical pathwa...
Heart Rhythm, 2015
ABBREVIATIONS ACEi = angiotensin-converting enzyme inhibitor; AF=atrial fibrillation; A-II=angiotensin-II; ANP=atrial natriuretic peptide; ARB = angiotensin receptor blocker; BP = blood pressure; BMI = body mass index; BNP = brain natriuretic peptide; CaMKII = calmodulin-dependent kinase II; DAD = delayed afterdepolarization; EAD = early afterdepolarization; ECM = electrocardiographic mapping; EHR = electronic health record; ET-1 = endothelin-1; GGA = geranyl-geranylacetone; GP = ganglionated plexi; HDAC6=histone deacetylase-6; HF=heart failure; HSP=heat shock protein; LA = left atrium; LAA = left atrial appendage; LGE-CMR = late gadolinium enhanced cardiac magnetic resonance imaging; LV = left ventricle; MRI = magnetic resonance imaging; NIH = National Institutes of Health; NOAC = non-vitamin K-dependent oral anticoagulant; NP = natriuretic peptide; OAC = oral anticoagulant; PAC = premature atrial contraction; pAF = paroxysmal atrial fibrillation; PV = pulmonary vein; PVI = pulmonary vein isolation; RAAS = renin-angiotensin-aldosterone system; RCT = randomized controlled trial; RSD= renal sympathetic denervation; SDB = sleep disordered breathing; SR = sarcoplasmic reticulum; TGF = transforming growth factor; TTR = time in therapeutic range (Heart Rhythm 2015;12:e5-e29)
European Heart Journal
With the procedure tailored to the local characteristics of heart muscle and delivering real-time feedback on whether the lesion has been effective, he sees di-electric sensing as a 'prime example of personalized stratified precision medicine'. Professor Ng is hopeful there will be benefits for the patient and the cardiologist with improved procedure outcomes and safety, a reduction in the need for patients to return for a repeat procedure and less use of X-ray and radiation. He added that the initial results are 'very promising'.